Quantinno Capital Management LP Invests $254,000 in Oruka Therapeutics, Inc. $ORKA

Quantinno Capital Management LP acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,176 shares of the company’s stock, valued at approximately $254,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Viking Global Investors LP bought a new position in Oruka Therapeutics in the 3rd quarter worth $51,280,000. Deep Track Capital LP boosted its holdings in Oruka Therapeutics by 38.4% during the third quarter. Deep Track Capital LP now owns 2,654,781 shares of the company’s stock valued at $51,051,000 after acquiring an additional 735,983 shares during the period. Vanguard Group Inc. grew its position in shares of Oruka Therapeutics by 38.1% in the fourth quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company’s stock valued at $74,366,000 after purchasing an additional 676,865 shares during the last quarter. RTW Investments LP grew its position in shares of Oruka Therapeutics by 5.8% in the fourth quarter. RTW Investments LP now owns 2,058,148 shares of the company’s stock valued at $62,382,000 after purchasing an additional 112,499 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new position in shares of Oruka Therapeutics in the fourth quarter worth about $51,840,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Oruka Therapeutics

In related news, Director Carl Dambkowski sold 12,583 shares of the company’s stock in a transaction on Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the transaction, the director directly owned 38,743 shares in the company, valued at approximately $2,716,271.73. This represents a 24.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $111.84, for a total value of $782,880.00. Following the completion of the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at approximately $3,659,181.12. This trade represents a 17.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 83,116 shares of company stock worth $6,636,533 over the last quarter. 23.49% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. UBS Group boosted their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a report on Thursday, April 30th. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a research report on Tuesday, August 11th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Finally, Piper Sandler reissued an “overweight” rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $134.30.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $102.42 on Tuesday. Oruka Therapeutics, Inc. has a twelve month low of $14.34 and a twelve month high of $115.51. The stock has a market cap of $6.78 billion, a PE ratio of -50.45 and a beta of -0.34. The firm has a 50-day simple moving average of $92.49 and a 200 day simple moving average of $65.93.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Research analysts forecast that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current fiscal year.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.